Hematology
| 4 min read
Phase 2 study achieves primary endpoint, with topical endoxifen rapidly reducing breast density
| 3 min read
Catalyst Biosciences’ FVIIa variant meets all endpoints in Phase 2 trial
| 4 min read
Hesperos’ heart-liver Human-on-a-Chip correctly determines cardiotoxic mechanisms preclinically
| 10+ min read
The 2019 ASHG meeting will feature the latest research on human genetics
| 3 min read
FDA approves Bayer’s Nubeqa (darolutamide) for men with non-metastatic castration-resistant prostate cancer
| 3 min read
Some tumors can bypass the immune system by reactivating an embryonic gene
| 2 min read
Ascentage Pharma to initiate Phase 1b study of HQP1351 in tyrosine kinase inhibitors-resistant chronic myeloid leukemia patients in the U.S.
| 3 min read
A look at a recent FDA decision and analyst forecasts in the field of liquid biopsy
| 10+ min read
It’s never just been about killing or removing tumors; it’s about aiming at them accurately
| 3 min read
The pharma giant is gearing up to acquire Array BioPharma for $11.4 billion
| 2 min read
Be The Match BioTherapies and TrakCel partner to standardize cell and gene therapy supply chain solutions
